Option Care Health Inc SEC Filings

Sethna Meenal reported acquisition or exercise transactions in this Form 4 filing.

Option Care Health, Inc. Chief Financial Officer Meenal Sethna reported an equity award of 27,045 shares of common stock, received as a grant with no cash price per share. These restricted stock units vest in three equal annual installments, and her directly held common stock increased to 82,112 shares after the award.

Option Care Health, Inc. reported that General Counsel and Corporate Secretary Collin Smyser acquired 15,213 shares of common stock through an equity award coded as a grant or other acquisition. The award consists of restricted stock units that vest in three equal installments on each of the first, second, and third anniversaries of the grant date.

After this grant, Smyser directly owns 94,215 shares of common stock. In addition, 2,500 shares are held indirectly through a revocable trust, reflecting separate indirect ownership.

Option Care Health, Inc. disclosed that its board of directors has increased the authorization for its 2025 share repurchase program from $500 million to $1 billion, with no specified expiration date. The company may buy back stock through open market purchases, privately negotiated transactions, block trades, or accelerated and other structured repurchase programs, with volume and timing determined by management based on market, regulatory, and corporate factors.

The company also furnished a press release with preliminary financial results for the three and twelve months ended December 31, 2025 and preliminary expectations for full year 2026, and an investor presentation tied to its appearance at the 44th Annual J.P. Morgan Healthcare Conference.

Option Care Health (OPCH) reported an insider purchase by a director. On November 3, 2025, the reporting person bought 38,000 shares of common stock at a weighted average price of $25.984 per share, executed across multiple trades priced between $25.835 and $26.235.

Following this transaction, the director beneficially owned 413,390 shares, held directly. The filing notes the weighted average and offers to provide detailed trade-by-trade pricing upon request.

Option Care Health (OPCH) filed its Q3 2025 10‑Q, reporting solid growth with stable profitability. Net revenue rose to $1,435,016,000 from $1,278,546,000, up 12.2% year over year, driven by increased acute and chronic therapy volumes. Gross profit was $272,902,000 versus $256,749,000, while operating income held at $84,507,000. Net income was $51,816,000 compared with $53,856,000, and diluted EPS was $0.32 versus $0.31.

For the first nine months, revenue reached $4,184,073,000 and net income was $149,081,000. The company closed the Intramed Plus acquisition for $117,247,000 (net of cash), adding referral sources and trademarks and increasing goodwill. It refinanced its First Lien Term Loan, cutting the rate to Term SOFR plus 1.75% and extending maturity to September 22, 2032, and added $49,600,000 of incremental debt. Cash from operations was $222,556,000; cash ended at $309,822,000. OPCH repurchased 6,805,621 shares year‑to‑date for $212,500,000, with $287,500,000 remaining under its authorization. Shares outstanding were 160,108,000 as of September 30, 2025.

Option Care Health (OPCH) furnished an update on its business by announcing it issued a press release with third quarter 2025 financial results. The press release is attached as Exhibit 99.1 to this Form 8-K. The company states the materials are furnished, not filed, which limits Exchange Act liability and incorporation by reference unless specifically noted.

The press release includes non-GAAP financial measures with reconciliations to the most comparable GAAP metrics. OPCH’s common stock trades on the Nasdaq Global Select Market under the symbol OPCH.

Option Care Health reported a Form 4 disclosing that Meenal Sethna, the company’s Chief Financial Officer, received an award of 55,067 restricted stock units in a transaction dated 10/01/2025. The units were issued at a price of $0 and are shown as directly beneficially owned at 55,067 shares following the award. The filing notes the restricted stock units "vest on the third anniversary of the grant date," and the Form 4 was signed on behalf of Ms. Sethna by an attorney-in-fact on 10/03/2025. The disclosure is a standard insider compensation award reported under Section 16 rules and contains no additional financial results, sales, or derivative transactions.

Option Care Health CFO Meenal Sethna filed an initial Form 3 under Section 16 reporting her relationship to the issuer as Chief Financial Officer and a director/officer. The filing states no securities are beneficially owned as of the event date 10/01/2025, and the form was signed on 10/03/2025.

Option Care Health entered into a Fourth Amendment to its First Lien Credit Agreement that refinances its existing term loans into a new seven-year tranche priced at Term SOFR plus 1.75%. The amendment also provides for incremental term loans totaling $49,639,386.20 at the same rate and maturity, and extends the maturity of the revolving credit commitments to the fifth anniversary of the amendment, subject to a springing maturity 91 days prior to the Unsecured Notes maturity if any Unsecured Notes remain outstanding. After the amendment, the principal amount of First Lien Term Loan indebtedness is approximately $678,000,000. The amendment was executed by the company and Bank of America, N.A., as administrative agent.